Biodistribution of sodium borocaptate (BSH) for boron neutron capture therapy (BNCT) in an oral cancer model
Biodistribution of sodium borocaptate (BSH) for boron neutron capture therapy (BNCT) in an oral cancer model
复制标题
DOI：
10.1007/s00411-013-0467-8
复制
发表时间：
2013-08-01
影响因子：
1.7
通讯作者：
Schwint, Amanda E.
中科院分区：
文献类型：
--
作者：
Garabalino, Marcela A.;Heber, Elisa M.;Schwint, Amanda E.
硼中子俘获疗法 (BNCT) 基于 B-10 载流子在肿瘤中的选择性积累，然后进行中子照射。我们之前证明了硼化合物硼苯丙氨酸和十氢十硼酸钠（GB-10）介导的BNCT在仓鼠颊囊口腔癌模型中的治疗成功。基于硼载体硼己酸钠（BSH）的临床相关性以及优化BNCT的最有效方法是提高肿瘤硼靶向性的认识，本研究的具体目的是在仓鼠颊囊口腔癌模型中进行BSH的生物分布研究，并评估BSH在RA-3核反应堆介导的BNCT的可行性。这些研究的总体目标是增进 BNCT 放射生物学知识并优化头颈癌的 BNCT。给荷瘤仓鼠施用硼己酸钠（50 mg B-10/kg）。 3-5只动物为一组，在给药后3-12小时的9个时间点被人道处死。对血液、肿瘤、癌前储袋组织、正常储袋组织和其他临床相关正常组织的样本进行处理，用于通过光学发射光谱法进行硼测量。肿瘤硼浓度达到治疗有用硼浓度值24-35 ppm的峰值。肿瘤/正常储袋组织的硼浓度比范围为1.1至1.8。药代动力学曲线显示BSH给药与中子照射的最佳间隔时间为7~11 h。结论是，在 RA-3 核反应堆上由 BSH 介导的 BNCT 是可行的。
Boron neutron capture therapy (BNCT) is based on selective accumulation of B-10 carriers in tumor followed by neutron irradiation. We previously proved the therapeutic success of BNCT mediated by the boron compounds boronophenylalanine and sodium decahydrodecaborate (GB-10) in the hamster cheek pouch oral cancer model. Based on the clinical relevance of the boron carrier sodium borocaptate (BSH) and the knowledge that the most effective way to optimize BNCT is to improve tumor boron targeting, the specific aim of this study was to perform biodistribution studies of BSH in the hamster cheek pouch oral cancer model and evaluate the feasibility of BNCT mediated by BSH at nuclear reactor RA-3. The general aim of these studies is to contribute to the knowledge of BNCT radiobiology and optimize BNCT for head and neck cancer. Sodium borocaptate (50 mg B-10/kg) was administered to tumor-bearing hamsters. Groups of 3-5 animals were killed humanely at nine time-points, 3-12 h post-administration. Samples of blood, tumor, precancerous pouch tissue, normal pouch tissue and other clinically relevant normal tissues were processed for boron measurement by optic emission spectroscopy. Tumor boron concentration peaked to therapeutically useful boron concentration values of 24-35 ppm. The boron concentration ratio tumor/normal pouch tissue ranged from 1.1 to 1.8. Pharmacokinetic curves showed that the optimum interval between BSH administration and neutron irradiation was 7-11 h. It is concluded that BNCT mediated by BSH at nuclear reactor RA-3 would be feasible.